Controlled Ovarian Stimulation Initiated at Different Phases of the Menstrual Cycle for Fertility Preservation in Oncological Patients: a Retrospective Study

被引:0
作者
A. Santolaria Baig
N. García Camuñas
P. Polo Sánchez
J. Subirá Nadal
S. Monzó Fabuel
J. M. Rubio Rubio
机构
[1] University and Polytechnic La Fe Hospital,Human Reproduction Unit
[2] IVIRMA,undefined
来源
Reproductive Sciences | 2023年 / 30卷
关键词
Random start; Controlled ovarian stimulation; Fertility preservation; Oncological patients; FORT; FOI;
D O I
暂无
中图分类号
学科分类号
摘要
The purpose of this study is to compare conventional start in early follicular phase (EFP) with late follicular phase (LFP) and luteal phase (LP) in controlled ovarian stimulation (COS) for fertility preservation (FP) to assess differences in clinical outcomes. Retrospective study of the first cycles of COS for FP in oncological patients between 2012 and 2020 in a tertiary hospital. Two-hundred forty-eight cycles were classified into 3 groups: 176 cycles in EFP, 8 cycles in LFP, and 52 cycles in LP. Comparing LFP to EFP, there were no differences in number of oocytes (10.0 [6.3–16.0] vs 12.0 [8.0–18.0]; p = 0.253) or number of metaphase II (MII) obtained (7.0 [2.3–13.3] vs 9.0 [6.0–13.0]; p = 0.229). Total number of days needed was higher in LFP (14.5 [12.5–16.0] vs 3.0 vs 10.0 [8.3–11.0 p = 0.000) but without significant differences in number of days of usage of gonadotropins (11.5 [8.3–12.8] vs 10.0 [8.3–11.0] p = 0.308). No differences were found between LP and EFP in number of oocytes (14.5 [9.0–20.0] p = 0.151) or MII (11.5 [7.0–16.0] p = 0.084). Number of days of gonadotropins (11.0 [10.0–12.0] p = 0.00) and total dosing (3000.0 [2475.0–3600.0] p = 0.013) were significantly higher in LP. FORT and FOI were similar in all groups. COS with a random start in fertility preservation has similar outcomes to EFP start. Therefore, we can initiate COS at any phase of the menstrual cycle with optimal results. However, LP may need more days of stimulation.
引用
收藏
页码:2547 / 2553
页数:6
相关论文
共 68 条
  • [1] Arnold M(2019)Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study Lancet Oncol 20 1493-1505
  • [2] Rutherford MJ(2013)Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update J Clin Oncol 31 2500-2510
  • [3] Bardot A(2016)Fertility preservation: fertility preservation in women with cancer J Pediatr Adolesc Gynecol [Internet] 31 1-10
  • [4] Loren AW(2011)Oocyte cryopreservation as a fertility preservation measure for cancer patients Reprod Biomed Online [Internet] 23 323-333
  • [5] Mangu PB(2013)(2013) Effective method for emergency fertility preservation: random-start controlled ovarian stimulation Fertil Steril [Internet] 100 1673-1680
  • [6] Beck LN(2018)Specific protocols of controlled ovarian stimulation for oocyte cryopreservation in breast cancer patients Curr Oncol 25 e527-e532
  • [7] Corkum KS(2017)Long-acting recombinant follicle-stimulating hormone in random-start ovarian stimulation protocols for fertility preservation in women with cancer Acta Obs Gynecol Scand 96 949-953
  • [8] Rhee DS(2018)Ovarian response after random-start controlled ovarian stimulation to cryopreserve oocytes in cancer patients J Bras Reprod Assist 22 352-354
  • [9] Wafford QE(2018)(2018) Ovarian response and follow-up outcomes in women diagnosed with cancer having fertility preservation: comparison of random start and early follicular phase stimulation - cohort study Eur J Obstet Gynecol Reprod Biol [Internet] 230 10-14
  • [10] Noyes N(2016)Timing of ovarian stimulation in patients prior to gonadotoxic therapy: an analysis of 684 stimulations Eur J Obstet Gynecol Reprod Biol [Internet] 199 146-149